Ribociclib-Induced Vitiligo: A Case Report with Histological, Dermatoscopic, Confocal Microscopy, and LC-OCT Findings Along with a Narrative Literature Review
Dermatology Practical & Conceptual · 31.07.2026 · 16 (3) · 6849
DOI: 10.5826/dpc.1603a6849 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Dermatology Practical & Conceptual, online erschienen am 31.07.2026. Verfasst von Silvia Mezi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
CDK4/6 inhibitors have revolutionized the therapeutic management of metastatic estrogen receptor-positive (ER+), HER2-negative breast cancer (BC) by increasing treatment efficacy while maintaining a favorable safety profile. An exceedingly rare adverse event associated with these agents is the development of vitiligo-like skin depigmentation.
Objectives
This study aimed to characterize a case of ribociclib-induced vitiligo and investigate its underlying pathogenic mechanisms, with particular focus on vitiligo onset. We report the case of a 60-year-old postmenopausal female with metastatic, hormone-sensitive BC who experienced a durable partial remission during treatment with ribociclib in combination with aromatase inhibitors. During therapy, the patient developed hypopigmented lesions on her upper limbs 34 months after initiation of ribociclib, preceded by pruritus and erythema.
Methods
Reflectance confocal microscopy (RCM) optical coherence tomography (OCT), and histopathological examination were used.
Result
RCM and OCT proved valuable for real-time assessment and monitoring of skin changes, thereby informing clinical decisions regarding the management of skin toxicity. The presence of an inflammatory infiltrate, comprising lymphocytes and hyper-reflective inflammatory cells, suggests that inhibition of the CDK4/6 pathway may enhance antitumor activity beyond cell cycle arrest by modulating the immune response and promoting immune-mediated tumor control.
Conclusions
The observed alterations in melanocyte regression could represent evidence of systemic immune activation and autoimmunity influencing melanocyte viability. These mechanisms may have significant implications for improving patient prognosis.
Autor:innen und Institutionen
- Department of Radiological, Oncological and Pathological Science, Sapienza University of Rome, Rome, Italy.
- Dermatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Science, University of La Sapienza, Rome, Italy.
- Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
- IDI-IRCCS Istituto Dermopatico dell'Immacolata, Rome, Italy.
Zitieren
APA
Mezi, S., Persechino, F., Ascione, A., Chiavassa, A., Artemi, A., Capasso, C., Amato, S., Paganelli, A., & Pellacani, G. (2026). Ribociclib-Induced Vitiligo: A Case Report with Histological, Dermatoscopic, Confocal Microscopy, and LC-OCT Findings Along with a Narrative Literature Review. Dermatology Practical & Conceptual, 16(3), 6849. https://doi.org/10.5826/dpc.1603a6849
Vancouver
Mezi S, Persechino F, Ascione A, Chiavassa A, Artemi A, Capasso C, et al. Ribociclib-Induced Vitiligo: A Case Report with Histological, Dermatoscopic, Confocal Microscopy, and LC-OCT Findings Along with a Narrative Literature Review. Dermatology Practical & Conceptual. 2026;16(3):6849. doi:10.5826/dpc.1603a6849
BibTeX
@article{Mezi2026,
author = {Mezi, Silvia and Persechino, Flavia and Ascione, Andrea and Chiavassa, Antonella and Artemi, Adele and Capasso, Camilla and Amato, Simone and Paganelli, Alessia and Pellacani, Giovanni},
title = {Ribociclib-Induced Vitiligo: A Case Report with Histological, Dermatoscopic, Confocal Microscopy, and LC-OCT Findings Along with a Narrative Literature Review},
journal = {Dermatology Practical & Conceptual},
year = {2026},
volume = {16},
number = {3},
pages = {6849},
doi = {10.5826/dpc.1603a6849}
}
EUVIMED